Rodent Stroke Model Guidelines for Pre-clinical Stroke Trials (1st edition).

Abstract

Translational stroke research is a challenging task that needs long term team work of the stroke research community. Highly reproducible stroke models with excellent outcome consistence are essential for obtaining useful data from preclinical stroke trials as well as for improving inter-lab comparability. However, our review of literature shows that the infarct variation coefficient of commonly performed stroke models ranges from 5% to 200%. An overall improvement of the commonly used stroke models will further improve the quality for experimental stroke research as well as inter-lab comparability. Many factors play a significant role in causing outcome variation; however, they have not yet been adequately addressed in the Stroke Therapy Academic Industry Roundtable (STAIR) recommendations and the Good Laboratory Practice (GLP). These critical factors include selection of anesthetics, maintenance of animal physiological environment, stroke outcome observation, and model specific factors that affect success rate and variation. The authors have reviewed these major factors that have been reported to influence stroke model outcome, herewith, provide the first edition of stroke model guidelines so to initiate active discussion on this topic. We hope to reach a general agreement among stroke researchers in the near future with its successive updated versions.

Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration

“…94 This is crucial, since promising treatments validated in preclinical models usually fail in clinical trials. Although the validity of the STAIR's recommendations has not been always confirmed, [95][96][97] they represent a useful guide for researchers planning preclinical stroke studies by providing directions on the selection and execution of the animal model, the fundamentals of good scientific inquiry, the choice and measurement of outcomes, and the drug/treatment administration, including the route and time-window. [98][99][100] We have previously defined the dose-response curve and the time-window for the neuroprotective effects of acute i.p.…”

Pre- and Post-treatment with Cyclosporine a in a Rat Model of Transient Focal Cerebral Ischaemia with Multimodal MRI Screening

“…Our results clearly showed a difference in the effects of CsA when given before or after reperfusion onset. In intraluminal MCAO models, interspecies variability and interlaboratory differences in protocols are the source of significant variability in success and complication rates, and lesion volume (32). We minimized inter-animal lesion size variability by using MRI criteria for inclusion, allowing us to detect the protective effects of a pretreatment by CsA.…”

Guanosine Protects Against Cortical Focal Ischemia. Involvement of Inflammatory Response

“…The slices were immersed for 30 min in 2 % of 2,3,5-triphenyltetrazolium chloride ( [38,39]. The brain slices were analyzed with Image J software (NIH, Bethesda, MD, USA).…”